Aehr Test Systems Multiples Expand to 18.6x Forward Sales on $100.6M Backlog
Resolved · earnings · Occurred · Assessed · 1 sources
This assessment is dated 2026-09-22. Check what remains unresolved below before relying on it.
Does the new outlook change what the company is worth?
Valuation re-rating to 18.59x forward sales leaves AEHR sensitive to order push-outs or customer concentration in its $100.6M backlog.
| Question | What the evidence establishes |
|---|---|
| What was reported? | Reported factAehr Test Systems stock has risen 363% in 2026. |
| What else was confirmed? | Reported factThe company currently trades at 18.59 times forward sales, compared to a historical median around 6 times. |
| Does the valuation support acting? | Interpretation1 stored valuation assumptions for AEHR; the latest is dated 2026-07-14. |
| What would change the assessment? | UnknownAehr quarterly backlog burn-off rate — Upcoming fiscal disclosures on new test cell order bookings and backlog conversion |
What would this event cost your holdings?
Apply your own hypothetical returns to current holding values. The calculator does not infer security effects from this event.
Test this event against my holdingsReported facts
- · Aehr Test Systems stock has risen 363% in 2026.
- · The company currently trades at 18.59 times forward sales, compared to a historical median around 6 times.
- · Aehr maintains an order backlog of $100.6 million driven by semiconductor test demand.
Public research record
Research framework · page evidenceCompleted event assessment
valuation multiple compression risk against high backlog execution expectations
| Type | Claim | Scope |
|---|---|---|
| Assumption | Aehr Test Systems stock has risen 363% in 2026. | 2026-09-22 |
| Interpretation | valuation multiple compression risk against high backlog execution expectations | AEHR |
Countercase, invalidators, and sources
Rapid conversion of $100.6M backlog and further AI wafer test orders validate high forward multiples.
- · Aehr quarterly backlog burn-off rate — Upcoming fiscal disclosures on new test cell order bookings and backlog conversion
- AEHR at 18.59X Sales: Market Loves Its AI Story, But is Love Blind? · 2026-09-21
What remains unresolved
- Base path
- Stock consolidates recent gains as quarterly shipment pace normalizes.
- Adverse path
- Delivery delays or customer capex moderation trigger sharp multiple contraction.
- Supportive path
- Rapid conversion of $100.6M backlog and further AI wafer test orders validate high forward multiples.
- · Aehr quarterly backlog burn-off rate — Upcoming fiscal disclosures on new test cell order bookings and backlog conversionnext month
Evidence
- AEHR at 18.59X Sales: Market Loves Its AI Story, But is Love Blind?2026-09-21
“Aehr Test Systems (AEHR) has surged 363% in 2026 driven by AI semiconductor testing demand, but now trades at 18.59X forward sales - over 3x its historical median. While the company has strong backlog ($100.6M)...”
Supports: Aehr gained 363% in 2026, trades at 18.59x forward sales with $100.6M backlog.